This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

The European Hematology Association's annual meeting presents the latest news in hematology and its subspecialties with evidence-based approaches to diagnosis and treatment, recent clinical and ...

Geron Corporation (NASDAQ:GERN) is one of the best low priced pharma stocks to buy now. Earlier on May 28, Geron Corporation ...

Shahzad Raza, MD, discusses the phase 2 RedirecTT-1 study which investigated the combination of talquetamab and teclistamab for treating patients with relapsed/refractory multiple myeloma complicated ...

Patients with (RRMM) and extramedullary disease (EMD) represent a particularly high-risk population with historically poor outcomes. In a new phase 2 analysis presented at the European Hematology ...

Tuspetinib in combination with venetoclax and azacitidine (the TUS+VEN+AZA triplet) continues to demonstrate exciting antileukemic activity and safety across genetically diverse populations of newly ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib ...

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London and Past ...

ERA Congress 2025 marked a pivotal moment in nephrology this year, bringing together over 9,000 global experts to explore ...

Italy’s Robin Foà, MD, an iconic European clinician-researcher, has been at forefront of hematology’s transformation for half ...